Clinical Trial Update: N-Acetyl-L-Leucine for GM2 Gangliosidosis (Tay-Sachs and Sandhoff Disease) [Phase 2]

View source ↗

Summary

Phase 2 clinical trial of N-Acetyl-L-Leucine for GM2 gangliosidosis (Tay-Sachs and Sandhoff) has completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gm2 Gangliosidosis
• Sandhoff Disease
• Tay-sachs Disease

Drugs mentioned

• N-Acetyl-L-Leucine (N-acetyl-L-leucine)

Snippet

Sponsor: IntraBio Inc | Conditions: GM2 Gangliosidosis, Tay-Sachs Disease | Phase 2 | Status: COMPLETED | Results posted: 2024-03-12